Following PGE2 treatment, CEBPD induces miR-135a activation in astrocytes to inhibit THBS, suggesting that the CEBPD/miR135a/THBS1 axis may be a therapeutic target for the treatment of AD (Ko et al., 2015). The gene discussed is CEBPD; the disease is Alzheimer disease.